Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are diagnosed with multiple sclerosis (MS) later, according to a study ...

Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are diagnosed with multiple sclerosis (MS) later, according to a study ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are ...

Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...

Biogen (BIIB) guided for a decline in earnings and revenue for 2025 amid ongoing challenges in its multiple sclerosis product category, despite reporting stronger-than-expected fourth-quarter results.

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Detect, improves systemic sclerosis diagnosis with over 90% accuracy in capillaroscopy. The AI tool enhances capillary ...

Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Fecal microbiota transplantation with an anaerobic cultivated human intestinal microbiome failed to improve gastrointestinal symptoms in patients with systemic sclerosis, a phase 2 study showed.